# BPC-157: Research Overview — UK Peptides Lab > A literature summary of BPC-157 (Body Protection Compound 157): mechanism via VEGFR2 and angiogenesis, pharmacokinetics, rodent tissue-repair findings, first-in-human safety data, and regulatory status. Research-only, no medical advice. A stable gastric pentadecapeptide with a broad animal-model healing record and a very thin human dataset — studied over three decades, mainly in rodents, with a mechanism linked most consistently to new-vessel growth. ## The short version BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide of 15 amino acids, derived from the sequence of a protective protein found in human gastric juice. Over roughly three decades of preclinical research — predominantly in rats — it has been found to accelerate healing in a wide variety of tissue-injury models: tendons, ligaments, the gut wall, muscle, and peripheral nerve. The most consistent explanation for these effects is that BPC-157 promotes the growth of new blood vessels (angiogenesis) into damaged tissue, largely through the VEGFR2 pathway [16]. The honest caveat comes early and clearly: almost all of this evidence is in animals. A 2025 narrative review noted that only a handful of small human pilot studies have examined BPC-157 in people, rigorous large-scale trials are lacking, and the compound should be treated as investigational [14]. It is not approved as a medicine anywhere, it is prohibited in competitive sport by the World Anti-Doping Agency, and common online claims — weight loss, muscle building, testosterone increase — are not supported by the published science. This page reports what the literature shows; it is not medical advice and lists no human dose. ## What it is BPC-157 is a *stable gastric pentadecapeptide* — fifteen amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), synthetic in origin, derived from the partial sequence of the human gastric juice protein BPC. The designation *stable* reflects its resistance to acid and enzymatic degradation in the gastric environment — a property relevant to why a protein native to gastric juice might demonstrate cytoprotective effects on the stomach lining. Its molecular formula is C₆₂H₉₈N₁₆O₂₂. It appears in research catalogues under several designations: PL 14736, PLD-116, PL-10, and Bepecin (a research designation). It is sometimes called a *cytoprotective peptide* to reflect its observed cell-protective effects in animal models. It is not a hormone, not a growth-hormone secretagogue, and not structurally related to any approved drug. It is also not derived from or related to thymosin-β4 or thymosin alpha-1, which are entirely different molecular families. Pharmacologically, it behaves as a short-half-life peptide: formal pharmacokinetic characterisation in rats and dogs found a very short elimination half-life (under 30 minutes), modest intramuscular bioavailability (approximately 14–19% in rats, 45–51% in dogs), and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism [15]. ## How it works BPC-157's repair mechanism in animal models is most consistently attributed to pro-angiogenic signalling. The best-characterised pathway involves the vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR): BPC-157 has been shown to up-regulate VEGFR2 expression on endothelial cells, promote VEGFR2 internalisation, and activate the downstream VEGFR2-Akt-eNOS (endothelial nitric oxide synthase) signalling cascade — producing increased nitric oxide and driving new vessel formation [16]. In a rat hindlimb ischaemia model this translated to accelerated blood-flow recovery and increased vessel density; effects were blocked when endocytosis was inhibited. Additional proposed mechanisms in the literature include modulation of the FAK-paxillin complex (which governs cell migration into wounds), increased growth-hormone-receptor expression in tendon fibroblasts (potentially explaining the tendon-healing observations), and effects on several neurotransmitter systems in central nervous system models. These are less fully characterised than the VEGFR2 angiogenesis pathway and derive from specific models rather than from consistent cross-laboratory replication. Because BPC-157's repair effects are largely mediated through angiogenesis, there is a mechanism-based caution worth noting: tumour growth also depends on new blood-vessel formation, and VEGFR2 signalling is a known pro-tumorigenic pathway. This generates a theoretical concern — not a documented human harm — about the use of a pro-angiogenic compound in settings of active or suspected malignancy. ## What the research shows **Foundational cytoprotection in rats (2004).** Xue and colleagues demonstrated that BPC-157 reduced gastric ulcer area and accelerated ulcer healing in Wistar rats; intramuscular delivery produced greater protection than intragastric administration, and ulcer-formation inhibition ratios ranged from 45.7 to 65.6% at higher doses [17]. This paper established the basic gastric cytoprotective effect that gave the compound its name and launched the field. **VEGFR2 pro-angiogenic mechanism (2017).** Hsieh and colleagues formally characterised the angiogenic pathway — VEGFR2 up-regulation and internalisation, downstream VEGFR2-Akt-eNOS activation — in chick chorioallantoic membrane, rat hindlimb ischaemia models, and human vascular endothelial cell cultures [16]. This paper is the most complete mechanistic account of BPC-157's vessel-growth effects. **Pharmacokinetics in rats and dogs (2022).** The first formal PK/ADME characterisation found linear pharmacokinetics, a very short elimination half-life in both species, modest intramuscular bioavailability, and excretion via urine and bile [15]. These data matter for anyone thinking about what a dose in an animal model would need to look like and why direct extrapolation to humans is problematic. **2025 narrative review (the evidence appraisal).** McGuire and colleagues conducted a narrative review of BPC-157 for musculoskeletal healing and concluded that the preclinical record is broad but that human data are extremely limited — only a handful of small pilot studies — and that rigorous, large-scale controlled trials are lacking. They recommend treating BPC-157 as investigational [14]. One of their explicit flags is that a large share of the foundational literature derives from a single research group, limiting independent replication. **First-in-human IV safety pilot (2025).** Lee and Burgess administered intravenous BPC-157 at doses up to 20 mg in two healthy adults (a 58-year-old male and a 68-year-old female) and reported no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers [13]. This is a tiny, uncontrolled safety observation — two participants, no efficacy endpoint — and should be read as a preliminary safety signal only, not as efficacy or dose-range data. ## Reported effects, cautions and safety **Anecdotal community reports (anecdotal, not clinical evidence).** BPC-157 has a larger community of human research users than either of the other compounds on this desk. The most commonly reported benefit — described very frequently — is accelerated recovery from stubborn tendon, ligament, and joint injuries: tennis elbow, rotator cuff strains, old sprains. Users describe these problems feeling more usable and less painful, often within the first one to three weeks. Improved digestive symptoms are also frequently reported — less bloating, cramping, and better food tolerance — consistent with the compound's gastric origins. Less common reports include improved sleep quality, steadier mood, faster wound healing, and a general reduction in perceived inflammation. Some of the sleep and mood reports may plausibly reflect secondary effects of reduced pain or better gut function rather than direct central action. On the adverse side, the most commonly reported complaint is a brief injection-site reaction — stinging, redness, or a small raised bump — described as typically fading within an hour. Mild nausea or stomach upset is noted by a minority, more often with oral products than injections, and usually passing quickly. A smaller group mention transient fatigue in the first week, mild headaches, occasional dizziness or lightheadedness shortly after injecting (attributed by some to the peptide's reported effects on vessel tone and the nitric-oxide system), or a wave of warmth or flushing in the first week. Palpitations are rarely mentioned; commentators treat persistent rapid heartbeat or chest pain as reasons to stop. **Documented cautions from the literature.** - *Extremely thin human evidence.* Almost all that is known comes from rodent studies; the 2025 review counts only a handful of small human pilots, and large controlled trials are absent [14]. - *Concentration of foundational research in one group.* A large proportion of the published record traces to a single research group; independent replication is limited and this should weight the reader's confidence accordingly [14]. - *Not an approved drug; unregulated supply chain.* BPC-157 is a research chemical; the FDA identified it in 2023 as not eligible for pharmacy compounding under 503A. Material from non-regulated suppliers has unverified identity, purity and sterility. - *Prohibited in competitive sport.* BPC-157 is banned at all times by the World Anti-Doping Agency under the non-approved substances category (S0). Athletes subject to testing face sanction risk. - *Theoretical oncology concern.* Strong pro-angiogenic activity via VEGFR2 raises a mechanism-based question about use in cancer contexts [16]. - *Unstudied in pregnancy, breastfeeding, and children.* No safety data exist for these populations. - *Long-term human safety is unknown.* The absence of long-term, large-n human safety data means the safety profile in people is genuinely unresolved. ## Where it fits in immune and tissue-repair research BPC-157 occupies the downstream, structural end of this desk's repair research framework. Once [Thymosin Alpha-1](/thymosin-alpha-1) has orchestrated a competent immune response and [KPV](/kpv) has helped resolve the local inflammatory environment, the tissue still needs physical reconstruction — new blood vessels to supply oxygen and nutrients, a scaffold of collagen, and migrating fibroblasts to rebuild the extracellular matrix. BPC-157's pro-angiogenic mechanism addresses the vascular reconstruction step, which is often rate-limiting in healing. This framing is a research conceptualisation, not a protocol recommendation. The three compounds have never been studied in combination in this context, and the desk does not suggest they should be. The framework is an intellectual organising device for reading the separate literatures. [Compare all three](/compare) on the compare page. --- A structured cross-reference of published research literature on immune and tissue-repair peptides — not a laboratory, not a vendor, and not a source of medical or dosing advice.